Label: PHOSLO- calcium acetate capsule
Contains inactivated NDC Code(s)
NDC Code(s): 54868-3460-0, 54868-3460-1, 54868-5691-0, 54868-5691-1
- Packager: Physicians Total Care, Inc.
- This is a repackaged label.
- Source NDC Code(s): 49230-640
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Updated March 10, 2010
If you are a consumer or patient please visit this version.
Each opaque gelcap with a blue cap and white body is spin printed in blue and white ink with “PhosLo®” printed on the cap and “667 mg” printed on the body. Each gelcap contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and 10 mg of the inert binder, polyethylene glycol 8000 NF. The gelatin cap and body have the following inactive ingredients: FD&C blue #1, D&C red #28, titanium dioxide, USP and gelatin, USP.
PhosLo Gelcaps (calcium acetate) are administered orally for the control of hyperphosphatemia in end stage renal failure.
Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate (PhosLo) when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. PhosLo is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Orally administered calcium acetate from pharmaceutical dosage forms has been demonstrated to be systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under nonfasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.
- INDICATIONS AND USAGE
Patients with end stage renal failure may develop hypercalcemia when given calcium with meals. No other calcium supplements should be given concurrently with PhosLo.
Progressive hypercalcemia due to overdose of PhosLo may be severe as to require emergency measures. Chronic hypercalcemia may lead to vascular calcification, and other soft-tissue calcification. The serum calcium level should be monitored twice weekly during the early dose adjustment period. The serum calcium times phosphate(CaXP) product should not be allowed to exceed 66. Radiographic evaluation of suspect anatomical region may be helpful in early detection of soft tissue calcification.
Excessive dosage of PhosLo induces hypercalcemia; therefore, early in the treatment during dosage adjustment serum calcium should be determined twice weekly. Should hypercalcemia develop, the dosage should be reduced or the treatment discontinued immediately depending on the severity of hypercalcemia. PhosLo should not be given to patients on digitalis, because hypercalcemia may precipitate cardiac arrhythmias. PhosLo therapy should always be started at low dose and should not be increased without careful monitoring of serum calcium. An estimate of daily calcium intake should be made initially and the intake adjusted as needed. Serum phosphorus should also be determined periodically.Information for the Patient
The patient should be informed about compliance with dosage instructions, adherence to instructions about diet and avoidance of the use of nonprescription antacids. Patients should be informed about the symptoms of hypercalcemia (see ADVERSE REACTIONS section).Drug Interactions
PhosLo may decrease the bioavailability of tetracyclines.Carcinogenesis, Mutagenesis, Impairment of Fertility
Long term animal studies have not been performed to evaluate the carcinogenic potential, mutagenicity, or effect on fertility of PhosLo.Pregnancy
Teratogenic Effects: Category C. Animal reproduction studies have not been conducted with PhosLo. It is not known whether PhosLo can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. PhosLo should be given to a pregnant woman only if clearly needed.Pediatric Use
Safety and effectiveness in pediatric patients have not been established.Geriatric Use
Of the total number of subjects in clinical studies of PhosLo (n=91), 25 percent were 65 and over, while 7 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
In clinical studies, patients have occasionally experienced nausea during PhosLo therapy. Hypercalcemia may occur during treatment with PhosLo. Mild hypercalcemia (Ca>10.5mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcemia (Ca>12mg/dl) is associated with confusion, delirium, stupor and coma. Mild hypercalcemia is easily controlled by reducing the PhosLo dose or temporarily discontinuing therapy. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing PhosLo therapy. Decreasing dialysate calcium concentration could reduce the incidence and severity of PhosLo induced hypercalcemia. The long-term effect of PhosLo on the progression of vascular or soft tissue calcification has not been determined.
Isolated cases of pruritus have been reported which may represent allergic reactions.
Administration of PhosLo in excess of the appropriate daily dosage can cause severe hypercalcemia (see ADVERSE REACTIONS section).
- DOSAGE AND ADMINISTRATION
Gelcap: A white and blue gelcap for oral administration containing 667 mg calcium acetate (anhydrous Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium.
NDC 54868-5691-0 Bottles of 200
NDC 54868-5691-1 Bottles of 100
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). See USP “Controlled Room Temperature.”
Fresenius Medical Care
Waltham, MA 02451
Repackaging and Relabeling by:
Physicians Total Care, Inc.
Tulsa, OK 74146
- PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
calcium acetate capsule
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:54868-5691(NDC:49230-640) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CALCIUM ACETATE (UNII: Y882YXF34X) (CALCIUM CATION - UNII:2M83C4R6ZB) CALCIUM ACETATE 667 mg Inactive Ingredients Ingredient Name Strength POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B) FD&C BLUE NO. 1 (UNII: H3R47K3TBD) D&C RED NO. 28 (UNII: 767IP0Y5NH) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) GELATIN (UNII: 2G86QN327L) Product Characteristics Color blue, white Score no score Shape CAPSULE Size 20mm Flavor Imprint Code PhosLo;667;mg Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:54868-5691-0 200 in 1 BOTTLE 2 NDC:54868-5691-1 100 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021160 03/01/2010 PHOSLO
calcium acetate capsule
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:54868-3460(NDC:49230-640) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CALCIUM ACETATE (UNII: Y882YXF34X) (CALCIUM CATION - UNII:2M83C4R6ZB) CALCIUM ACETATE 667 mg Inactive Ingredients Ingredient Name Strength POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B) FD&C BLUE NO. 1 (UNII: H3R47K3TBD) D&C RED NO. 28 (UNII: 767IP0Y5NH) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) GELATIN (UNII: 2G86QN327L) Product Characteristics Color blue, white Score no score Shape CAPSULE Size 20mm Flavor Imprint Code PhosLo;667;mg Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:54868-3460-0 30 in 1 BLISTER PACK 2 NDC:54868-3460-1 100 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021160 08/27/1997 10/11/2006 Labeler - Physicians Total Care, Inc. (194123980) Establishment Name Address ID/FEI Business Operations Physicians Total Care, Inc. 194123980 repack, relabel